Mimedx (MDXG) EBITDA (2011 - 2026)

Mimedx (MDXG) has 16 years of EBITDA data on file, last reported at -$16.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 294.51% year-over-year to -$16.0 million; the trailing twelve-month figure through Mar 2026 stood at $39.6 million (down 26.58% YoY), and the FY2025 full-year result was $63.9 million, up 8.53% from the prior year.
• EBITDA fell to -$16.0 million in Q1 2026, from $21.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $23.4 million in Q2 2024 to a low of -$16.0 million in Q1 2026.
• A 5-year average of $7.6 million and a median of $11.1 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 2250.24% in 2022 and jumped 3981.76% in 2024, its largest moves.
• Tracing MDXG's EBITDA over 5 years: stood at $11.3 million in 2022, then soared by 36.95% to $15.5 million in 2023, then retreated by 28.64% to $11.1 million in 2024, then jumped by 90.67% to $21.1 million in 2025, then sank by 176.14% to -$16.0 million in 2026.
• Business Quant data shows MDXG's EBITDA at -$16.0 million in Q1 2026, $21.1 million in Q4 2025, and $22.2 million in Q3 2025.